Research Progress of Long Non-coding RNA in Acute Myeloid Leukemia--Review.

Author: Shu-E CUN ¹ ; Jiang-Ting ZHENG ¹ ; Rui LIU ¹ ; Lin ZHENG ¹ ; Yu-Ming WANG ²
Author Information

1. Clinical Laboratory, The Second Affiliated Hospital of Kunming Medical University, Kunming 650106, Yunnan Province, China.
2. Clinical Laboratory, The Second Affiliated Hospital of Kunming Medical University, Kunming 650106, Yunnan Province, China.E-mail: wangym992011@163.com.
Publication Type:Journal Article
Keywords: acute myeloid leukemia; drug resistance; long non-coding RNA; mechanism of action
MeSH: Humans; RNA, Long Noncoding/metabolism*; Leukemia, Myeloid, Acute/drug therapy*; Prognosis
From: Journal of Experimental Hematology 2023;31(1):287-291
CountryChina
Language:Chinese
Abstract: Long non-coding RNA (lncRNA) is not "transcriptional noise". It can regulate gene expression at pre-transcriptional, post-transcriptional and epigenetic level and participate in the occurrence and development of diseases. A large number of studies have shown that the abnormal expression of lncRNA plays an important role in the occurrence and development of acute myeloid leukemia (AML) and drug resistance. LncRNA can participate in the occurrence, development and drug resistance of AML by acting on target genes and regulating related signal pathways. Detection of its expression has a certain prognostic value. Therefore, this article briefly discusses the research progress of lncRNA in AML, hoping to provide ideas for clinical diagnosis and targeted therapy.